0QYQ.LSE Gilead Sciences Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.05%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0QYQ.LSE undervalued?
Graham numberThe Graham number of Gilead Sciences Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gilead Sciences Inc. fundamental analysis
No fundamental analysis for Gilead Sciences Inc. yet.
Gilead Sciences Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gilead Sciences Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus,…
Full company profileGilead Sciences Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gilead Sciences Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 26.1B | 22.1B | 22.4B | 24.7B | 27.3B | - | - |
| Gross Profit | 21.7B | 17.3B | 17.8B | 20.1B | 20.7B | - | - |
| Operating Income | 14.1B | 8.20B | 4.29B | 4.07B | 9.92B | - | - |
| Net Income | 4.63B | 5.46B | 5.39B | 123M | 6.23B | - | - |
| Balance Sheet | |||||||
| Total Assets | 70.3B | 63.7B | 61.6B | 68.4B | 68.0B | - | - |
| Total Liabilities | 49.8B | 42.3B | 39.1B | 50.2B | 46.9B | - | - |
| Shareholders' Equity | 20.4B | 21.4B | 22.5B | 18.2B | 21.1B | - | - |
| Cash & Short-term Investments | 25.5B | 30.1B | 24.4B | 7.41B | 7.83B | - | - |
| Total Debt | 30.8B | 24.6B | 22.1B | 28.6B | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | 11.9B | 8.40B | 9.14B | 8.17B | 11.4B | 9.07B | - |
| Capital Expenditure | 590M | 924M | 825M | 650M | 579M | 728M | 0.00 |
| Ratios | |||||||
| ROE | 22.6% | 25.5% | 23.9% | 0.7% | 29.6% | - | - |
| ROA | 6.6% | 8.6% | 8.7% | 0.2% | 9.2% | - | - |
| Net Profit Margin | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | - | - |
| Debt to Equity | 1.51x | 1.15x | 0.98x | 1.57x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gilead Sciences Inc. dividends
Gilead Sciences Inc. has not paid dividends in the last 8 fiscal years.
Who owns Gilead Sciences Inc.
- Insiders 0.11%
- Institutions 92.00%
- Public & others 7.90%
- Free float 1.24B
Gilead Sciences Inc. company profile
- Company name
- Gilead Sciences Inc.
- Ticker
- 0QYQ.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 17,000
- Fiscal year end
- December
- Address
- 333 Lakeside Drive, Foster City, CA, United States, 94404
- Phone
- 650 574 3000
- Website
- gilead.com
About Gilead Sciences Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences Inc. management
10- Mr. Daniel Patrick O'DayChairman & CEO · born 1965
- Mr. Andrew D. DickinsonExecutive VP & CFO · born 1970
- Ms. Johanna MercierChief Commercial & Corporate Affairs Officer · born 1970
- Dr. Dietmar P. Berger M.D., Ph.D.Chief Medical Officer · born 1969
- Ms. Erin E. BurkhartSenior VP, Controller & Chief Accounting Officer · born 1979
- Ms. Jacquie Ross C.F.A.Senior Vice President of Treasury & Investor Relations
- Ms. Keeley M. Cain WettanExecutive VP, General Counsel of Legal & Compliance and Secretary · born 1975
- Ms. Jyoti K. MehraExecutive Vice President of Human Resources · born 1976
- Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & Portfolio · born 1962
- Dr. Flavius Martin M.D.Executive Vice President of Research